Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
1Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 119228, Singapore.
2Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
Correspondence to: Dr. Joline SJ Lim, Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, 1E Kent Ridge Road, Singapore 119228, Singapore. E-mail:
The use of immune checkpoint inhibitors (ICIs) has increased exponentially in the past decade, although its progress specifically for breast cancer has been modest. The first U.S. Food and Drug Administration approval for ICI in breast cancer came in 2019, eight years after the first-ever approval of an ICI. At present, current indications for ICIs are relevant only to a subset of patients with triple-negative breast cancer, or those displaying high microsatellite instability or deficiency in the mismatch repair protein pathway. With an increasing understanding of the limitations of using ICIs, which stem from breast cancer being innately poorly immunogenic, as well as the presence of various intrinsic and acquired resistance pathways, ongoing trials are evaluating different combination therapies to overcome these barriers. In this review, we aim to describe the development timeline of ICIs and resistance mechanisms limiting their utility, and summarise the available approaches and ongoing trials relevant to overcoming each resistance mechanism.
Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cancer cases globally, and is the leading cause of cancer mortality in women. In the year 2020, an estimated 2.3 million female breast cancers were diagnosed globally, and about 685,000 women died from their disease. This number is expected to grow to more than 3 million new cases diagnosed and 1 million deaths by the year 2040.
With advances in our understanding of cancer biology, immuno-oncology has become an area of great interest and extensive research. Cancer immunotherapy employs the use of cutting-edge technologies, including immune checkpoint inhibitors (ICIs) such as those targeting Programmed Cell Death Protein-1 (PD-1), Programmed Cell Death Ligand-1 (PD-L1), and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), and more recently, chimeric antigen receptor (CAR) T cell therapies. Other frontiers being pushed in the realms of immunotherapy include the use of cancer vaccines, for cancer prevention, such as vaccines for Human Papilloma Virus and Hepatitis B, as well as in cancer treatment, as in the case of Sipuleucel-T for prostate cancer.
Since the first U.S. Food and Drug Administration (FDA) approval of ipilimumab, a CTLA-4 monoclonal antibody, in 2011 for the treatment of metastatic melanoma, ICIs have transformed the treatment landscape across multiple tumour types. There are now eleven FDA approvals for ICIs: two CTLA-4 inhibitors (ipilimumab, tremelimumab), five PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanlimab), three PD-L1 inhibitors (atezolizumab, avelumab, durvalumab), and one lymphocyte-activation gene 3 (LAG-3) blocking antibody (retatlimab)[6-9]. However, amongst the numerous available approvals for ICIs, there are currently only two specific FDA approvals in the setting of breast cancer, both for pembrolizumab in the subgroup of triple-negative breast cancer (TNBC), given in combination with chemotherapy in the metastatic and neoadjuvant settings. Additional FDA approvals that are tumour agnostic and apply to breast cancer include pembrolizumab and dostarlimab in breast cancers displaying high microsatellite instability (MSI-H) or a deficiency in the mismatch repair protein (dMMR) pathway. While one of the hallmarks of treatment with ICIs is its durable response that translates to prolonged survival of these patients, admittedly, only a very small subset of patients benefit. In this review article, we will first describe the evolution of ICI in the TNBC subtype, focusing on its approved indications, before delving into the understanding of the resistance mechanisms towards ICIs, and how we can harness such knowledge to develop new combination strategies.
EVOLUTION OF ICIS IN BREAST CANCER
Monotherapy ICIs in TNBC
Evidence for the use of ICIs in breast cancer first came from single-agent immunotherapy trials in the metastatic setting, including the KEYNOTE-012 and KEYNOTE-086 studies. KEYNOTE-012 was a phase I study that aimed to evaluate the role of single-agent pembrolizumab in patients with various advanced solid tumours. In the cohort of TNBC who had progressed on a median of 2 lines of treatment, the objective response rate (ORR) was 18.5% and 6-month progression-free survival (PFS) was 24.4%, 6-month and
KEYNOTE-086 was designed specifically to look at the role of pembrolizumab monotherapy in patients with metastatic TNBC. This phase II multicohort study included all comers with ≥ 1 prior systemic treatment for metastatic disease regardless of PD-L1 status (Cohort A), and also patients with no prior systemic treatment in the metastatic setting who had PD-L1 positive tumours defined as combined positive score (CPS) ≥ 1 based on the Dako PD-L1 IHC 22C3 platform (Cohort B). Comparing across cohorts, there was a suggestion of improved ORR in less heavily pre-treated patients (ORR 21.4% vs. 5.3%) in Cohort B vs. all-comers in Cohort A. This was consistent with other similar phase 1 trials evaluating avelumab (JAVELIN study) and atezolizumab (PCD4989g trial) as monotherapy in metastatic TNBC, suggesting clinical benefit when used in earlier lines of treatment and PD-L1 expressing tumours.
A subsequent KEYNOTE-119 randomised phase III trial compared pembrolizumab monotherapy vs. single agent physicians’ choice chemotherapy in patients who progressed on 1 or 2 prior lines of treatment for metastatic TNBC. While the trial was negative for its primary endpoint of OS in all subgroups, there was a positive trend to survival benefit in patients with PD-L1 CPS ≥ 10 (12.7 vs. 11.6 months, HR 0.78;
The limited efficacy of single-agent immunotherapy observed in breast cancer might be due to intrinsic tumour resistance due to its complex and enigmatic relationship with the immune system. Breast cancer was traditionally thought to be poorly immunogenic, also known as a “cold tumour”. Immunogenicity, or the ability to elicit an antitumoural response by the body’s immune system, is dependent upon the formation of neo-antigens that are derived from gene mutations, viral oncogenes alternative splicing, or gene rearrangement[20-22]. It is assessed by the antigenicity of a cancer, which in turn is evaluated by its mutagenicity. One measure of the antigenicity of cancer is its mutational load or tumour mutational burden (TMB), which refers to the average number of somatic mutations per (Mb)[23,24]. Cancers like melanoma and lung cancer are known to be “hot tumours”, as observed in a study by Chalmers et al. who reported their median TMB levels to be 13.5 mut/Mb and 7.2 mut/Mb, respectively. In contrast, the TMB in breast cancer is generally much lower. In a study by Barroso-Sousa et al. of 3,969 patients with breast cancer, the median TMB reported was 2.63 mut/Mb, while another Chinese study of 196 breast cancer patients demonstrated a higher median TMB of 4.03 mut/Mb. Due to the poor efficacy observed with the use of single-agent immunotherapy treatment, further efforts were directed at exploring combination treatment.
Combining ICIs with chemotherapy in TNBC
The rationale for combination treatment with chemotherapy was that chemotherapeutic agents had been shown to have synergistic effects with ICIs by inducing immunogenic cell death, causing the release of tumour-associated neoantigens as well as its ability to stimulate immune surveillance[28,29]. Indeed, this has proven to be an effective strategy in several subgroups of TNBC.
The initial results of several phase I studies evaluating this combination in the setting of metastatic TNBC were promising, reporting response rates ranging between 23.4%-39%[30,31]. Several phase III trials confirmed these positive preliminary findings, leading to the first FDA-approved indication for an ICI for use in breast cancer treatment.
The first FDA accelerated approval of an ICI for breast cancer was with the anti-PD-L1 inhibitor atezolizumab, which was granted on 8 March 2019 based on the IMpassion 130 trial. This phase III placebo-controlled randomised trial evaluated 902 patients with treatment naïve, unresectable locally advanced or metastatic TNBC. Patients were randomised to receive either atezolizumab or its placebo, in combination with albumin-bound paclitaxel (nab-paclitaxel). In patients whose tumours expressed PD-L1 based on the VENTANA PD-L1 SP142 assay, there was a significant median PFS benefit: 7.5 months in patients receiving atezolizumab vs. 5.0 months with placebo (HR 0.62, P < 0.001). The final approval of this combination was contingent upon the results of the IMpassion 131 trial evaluating atezolizumab with paclitaxel in TNBC in the same setting, which unfortunately failed to meet its primary endpoint of superior PFS. This led to Genentech voluntarily withdrawing the previously granted accelerated FDA approval for atezolizumab on 27 August 2021. Eventually, when the final OS was read out for the IMpassion 130 trial, the addition of atezolizumab to nab-paclitaxel failed to meet statistical significance, precluding further testing.
Pembrolizumab is currently FDA-approved for use in TNBC in the first-line metastatic and neoadjuvant settings, both in combination with chemotherapy. It first received FDA approval on 13 November 2020 as combination therapy with chemotherapy for patients with unresectable locally-advanced or metastatic TNBC whose tumours have a PD-L1 CPS ≥ 10 based on the Dako 22C3 assay. This was based on KEYNOTE-355, a phase III randomised placebo-controlled study evaluating the role of pembrolizumab in combination with chemotherapy in patients in the above-mentioned setting. It reported a median OS (mOS) benefit of about 7 months in patients whose tumours expressed PD-L1 CPS ≥ 10 (mOS 23.0 vs. 16.1 months; HR 0.73, P = 0.0185). In patients whose tumours expressed PD-L1 CPS ≥ 1 or in the intention-to-treat population, there was no survival benefit shown.
In addition, pembrolizumab also has tumour-agnostic FDA approval for advanced unresectable or metastatic solid tumours that are dMMR or MSI-H. This was based on the combined results of 5 single-arm trials where a total of 149 patients with dMMR/MSH-H solid tumours achieved an ORR of 39.6%, with 78% of patients having responses lasting 6 months or more. It should be noted, however, that only 2 out of the 149 patients had breast cancer. They both achieved partial responses, with duration of response (DoR) of 7.6 and 15.9 months.
Most recently, on 17 August 2021, dostarlimab also received accelerated FDA approval for recurrent or advanced solid tumours that are dMMR based on the GARNET trial. This was an open-label, non-randomised, multicohort phase I trial evaluating dostarlimab as monotherapy in the above-mentioned clinical setting. In these patients, there was an ORR of 41.6%, with 9.1% complete responses and 32.5% partial responses. The median DoR was 34.7 months, with 95.4% of patients still showing continued response at 6 months. In cohort F, which enrolled 106 non-endometrial solid tumours, 1 patient had dMMR breast cancer and reported a complete response.
With the promising results of a combination of ICI therapy and chemotherapy in the metastatic setting, efforts were then shifted to study it in the earlier curative stages of breast cancer. One of these trials is the phase II I-SPY 2 trial, which adopted an adaptive trial design to evaluate various novel therapeutics in combination with chemotherapy, comparing that to standard treatment as in the neoadjuvant setting for early-stage breast cancer. Pembrolizumab was included in one of the study arms, where patients were randomised to receive 4 cycles of pembrolizumab given in combination with weekly paclitaxel vs. weekly paclitaxel alone, followed by doxorubicin/cyclophosphamide and then definitive surgery. Compared to standard chemotherapy alone, the addition of pembrolizumab improved pathologic complete response (pCR) rates in all breast cancer subtypes: 44% vs. 17% in HER2-negative breast cancers, 30% vs. 13% in HR-positive/HER2-negative breast cancers, and 60% vs. 22% in TNBC.
Focusing on the TNBC subtype, the role of pembrolizumab in the neoadjuvant setting was proven in the confirmatory phase III KEYNOTE-522 trial, which subsequently led to pembrolizumab receiving its second breast cancer-specific FDA approval on 26 July 2021. In this phase III randomised controlled study, 1,174 patients with previously untreated stage II or III TNBC were randomised in a 2:1 ratio to receive pembrolizumab or a placebo, respectively, in combination with chemotherapy , before undergoing surgery. Pembrolizumab or its placebo was continued post-operatively for up to 9 cycles. Both primary endpoints of the trial were met; there was a significant improvement in pCR of 64.8% vs. 51.2%; P = 0.00055, although this had reduced by the third interim analysis to 63.0% vs. 55.6%. There was also an improvement in
The benefit of ICIs in combination with chemotherapy in the neoadjuvant setting was also echoed in the IMpassion 031 study evaluating atezolizumab. In IMpassion 031, atezolizumab was evaluated in the neoadjuvant setting in patients with stage II-III TNBC treated for curative intent. This was a double-blind phase III randomised trial where patients received either atezolizumab or its placebo, in combination with nab-paclitaxel, followed by doxorubicin and cyclophosphamide. The investigators found an increase in pCR rates from 58% vs. 41% in the all-comers population; P = 0.0044, (significance boundary 0.0184), and 69% vs. 49% in PD-L1 positive patients; P = 0.021, (significance boundary 0.0184). As it did not hit the prespecified boundary of significance for its second co-primary endpoint, the study is not formally powered for further survival analyses.
However, not all trials evaluating the addition of ICIs in combination with chemotherapy in the neoadjuvant setting for TNBC have yielded similar results. Both the NeoTRIP and GeparNeuvo evaluating atezolizumab and durvalumab, respectively, in the neoadjuvant setting were negative for pCR benefit. Patients in the NeoTRIP study were randomised to receive neoadjuvant carboplatin and nab-paclitaxel with or without 8 cycles of atezolizumab. Anthracyclines were given in the adjuvant setting after definitive surgery. The addition of atezolizumab resulted in numerically higher but nonsignificant pCR rates: 48.6% vs. 44.4%; P = 0.48. Similarly, the GeparNuevo trial studied the addition of durvalumab to neoadjuvant chemotherapy with paclitaxel followed by epirubicin and cyclophosphamide, which found a nonsignificant but numerically superior pCR rates of 53.4% vs. 44.2%; P = 0.224. Interestingly, a survival benefit with the addition of durvalumab compared to placebo was observed; 3-year invasive disease-free survival (iDFS) was 84.9% vs. 76.9% (HR 0.54; P = 0.0559) and 3-year OS 95.1% vs. 83.1% (HR 0.26; P = 0.0076).
While there is general consensus for the use of ICIs in combination with chemotherapy in the neoadjuvant setting for TNBC, its optimal duration is currently still widely discussed. In both KEYNOTE-522 and IMpassion 031, the ICI was continued post-operatively for a total of 1 year, while NeoTRIP and GeparNuevo only administered ICI in the neoadjuvant setting. GeparNuevo is the only study that has shown survival benefits with the use of ICI despite being administered only in the neoadjuvant context without continuation in the adjuvant setting, leading to questions of whether there is a need for continual ICI in the adjuvant setting. Additionally, the pCR benefit that was observed in the durvalumab group in GeparNuevo was exclusively seen in the cohort of patients who received a 2-week lead-in of durvalumab prior to chemotherapy, although the reason for this observation is currently unclear. We have summarised the trials evaluating the use of ICI both as monotherapy and in combination with chemotherapy in Table 1.
Summary of trials evaluating the use of ICI as monotherapy and in combination with chemotherapy
|I||Advanced TNBC, PD-L1 + ve; pre-treated||Pembrolizumab||ORR 18.5%
6-mo PFS 24.4%
6-mo OS 66.7%, 12-mo OS 43.1%
|II||Metastatic TNBC; pre-treated
Cohort A: all-comers
Cohort B: PD-L1 + ve
|Pembrolizumab||Cohort A: ORR 5.3%, mPFS 2.0 mo, mOS 9.0 mo
Cohort B: ORR 21.4%, mPFS 2.1 mo, mOS 18.0 mo
|I||Metastatic breast cancer; pre-treated||Avelumab||ORR: 3.0% (overall population), 5.2% (TNBC), 16.7% (PD-L1 + ve), 1.6% (PD-L1-ve)|
|I||Metastatic TNBC; any-line||Atezolizumab||ORR 24% (1st line), 6% (≥ 2nd line)
ORR 12% (1st line), 0% (≥ 2nd line)
mOS 10.1 mo (PD-L1 + ve), 6.0 mo (PD-L1-ve)
|III||Metastatic TNBC; 1 or 2 prior lines||Pembrolizumab vs. chemotherapy||mOS 9.9 mo vs. 10.8 mo HR 0.97 (overall population)
mOS 12.7 mo vs. 11.6 mo HR 0.78; P = 0.057 (PD-L1 CPS ≥ 10)
|III||Metastatic TNBC; untreated||Nab-paclitaxel +/- atezolizumab||mPFS 7.2 mo vs. 5.5 mo, HR 0.79; P = 0.002 (ITT)
mOS 21.0 mo vs. 18.7 mo HR 0.87; P = 0.077 (ITT)
mPFS 7.5 mo vs. 5.0 mo HR 0.63, P < 0.0001 (PD-L1 + ve)
mOS 25.4 mo vs. 17.9 mo HR 0.67; (PD-L1 + ve)
|III||Metastatic TNBC; untreated||Paclitaxel +/- atezolizumab||mPFS 6.0 mo vs. 5.7 mo, HR 0.82; P = 0.20 (PD-L1 + ve)
mPFS 5.7 mo vs. 5.6 mo, HR 0.86 (ITT)
|III||Metastatic TNBC; untreated||Chemotherapy +/- pembrolizumab||mPFS 9.7 mo vs. 5.6 mo HR 0.66 (CPS ≥ 10)
mPFS 7.6 mo vs. 5.6 mo HR 0.75
mOS 23.0 vs. 16.1 mo HR 0.73; P = 0.0185 (CPS ≥ 10)
mOS 17.6 mo vs. 16.0 mo HR 0.86 P = 0.1125 (CPS ≥ 1)
|II||High-risk stage II/III breast cancer||Chemotherapy +/- pembrolizumab||pCR 44% vs. 17% (ERBB2-negative), 30% vs. 13% (HR- + ve/ERBB2-ve), 60% vs. 22% (TNBC)|
|III||Stage II/III TNBC||Chemotherapy +/- pembrolizumab||pCR 64.8% vs. 51.2%; P = 0.00055
3yr EFS 84.5% vs. 76.8% HR 0.63; P < 0.001
|III||Stage II/III TNBC||Chemotherapy +/- pembrolizumab||pCR 58% vs. 41%; P = 0.0044 (all-comers)
pCR 69% vs. 49% P = 0.021 (significance boundary 0.0184) (PD-L1 + ve)
|III||Early high-risk and locally advanced TNBC||Chemotherapy +/- atezolizumab followed by surgery, then adjuvant anthracyclines||pCR 48.6% vs. 44.4% OR 1.18; P = 0.48|
|II||Non-metastatic TNBC||Chemotherapy +/- durvalumab
*window phase included 2 weeks of durvalumab/placebo
|pCR 53.4% vs. 44.2% OR 1.45; P = 0.224
3yr iDFS 84.9% vs. 76.9% HR 0.54; P = 0.0559
3yr OS 95.1% vs. 83.1% HR 0.26; P = 0.0076
In the adjuvant setting, there are ongoing trials such as the A-BRAVE trial investigating the use of avelumab in the treatment of high-risk TNBC, as well as the ALEXANDRA/IMpassion030 trial evaluating standard chemotherapy with or without atezolizumab in patients with early-stage TNBC. Additionally, the use of ICIs in early relapsing TNBC is also being investigated in the IMpassion 132 trial, a phase III randomised trial evaluating the role of combining atezolizumab with chemotherapy in patients with locally recurrent inoperable or metastatic TNBC within 12 months from receiving curative-intent treatment.
ICIs in other subtypes of breast cancer
While there have also been efforts to evaluate the use of ICIs in HER2-positive and hormone-positive/HER2-negative breast cancers, none of the studies have led to conclusive evidence for its use in these settings at present. In particular, HER2-positive breast cancer is thought to share certain similarities with TNBC that might suggest a benefit from ICI therapy. This includes the presence of higher tumour infiltrating lymphocytes (TILs) and PD-L1 expression. The presence of TILs in the tumour and its surrounding microenvironment is thought to be a reflection of pre-existing antitumour immunity[49,50], and its presence is thought to be predictive of response to systemic anti-cancer treatment, as well as a prognostic biomarker. TNBC and HER2-positive breast cancers have been observed to have a higher number of TILs compared to hormone-positive breast cancers[51,52]. PD-L1 expression has also been observed to be upregulated in HER2-positive breast cancer, and be predictive of response to ICIs in the PANACEA and KATE2 studies[54,55]. Further in-depth discussion of ICIs in HER2-positive and hormone-positive/HER2-negative breast cancers is beyond the scope of our current article, but has been extensively reviewed[56-58].
UNDERSTANDING AND OVERCOMING RESISTANCE MECHANISMS TO ICIS
Given that the earliest approval for ICI use in breast cancer came on 8 March 2019 for atezolizumab in combination with nab-paclitaxel in metastatic TNBC based on the IMpassion 130 trial, the experience and evidence available on resistance mechanisms specific to immunotherapy in breast cancer is scarce. In addition, discounting tumour agnostic approvals, which form a very small proportion of breast cancer patients as discussed above[36,37], the approval for ICIs in breast cancer is now only limited to the TNBC subtype, which constitutes only 15%-20% of all patients with breast cancer, and even so, only a subset of them with high risk early-stage and metastatic disease. Hence, much of our understanding of resistance to ICIs comes from the available data and research on ICI treatment as a whole from various other tumour types.
Resistance pathways to ICIs can be tumour-intrinsic, e.g., alteration of certain genes or signalling pathways within the tumour, or tumour-extrinsic, e.g., changes in components within the tumour microenvironment (TME) other than the tumour cell itself. This can happen either from the outset, conferring primary resistance whereby no response to treatment is noted, or after a period of observed response, highlighting the concept of acquired resistance. As previously mentioned, breast cancers are known to be immunogenically cold tumours, which contributes to their primary resistance to ICI. We will discuss the various mechanisms of resistance by looking at both tumour-intrinsic and tumour-extrinsic pathways, and how each of them might potentially be harnessed to overcome drug resistance [Figure 1].
Figure 1. Tumour intrinsic and extrinsic resistance pathways to ICIs. Created with BioRender.com. AKT: Protein kinase B; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; IFN-γ: interferon-γ; JAK: janus kinase; LAG-3: lymphocyte-activation gene 3; MAPK: mitogen-activated protein kinase; MDSC: myeloid-derived suppressor cell; MHC-I: major histocompatibility complex-I; mTOR: mammalian target of rapamycin; PD-1: programmed cell death protein-1; PD-L1: programmed cell death ligand-1; PI3K: phosphatidylinositol 3-kinase; STAT: signal transducers and activators of transcription; TAM: tumour-associated macrophage; TGF-β: transforming growth factor-β; TIM-3: T-cell immunoglobulin, mucin domain-3 protein; T-reg: regulatory T cell; VISTA: V-domain immunoglobulin suppressor of T-cell activation.
TUMOUR INTRINSIC RESISTANCE MECHANISMS TO ICIS
Alteration of signalling pathways
There are several critical signalling pathways that control cell-cycle progression, apoptosis, and cell growth. Alterations in any of these pathways can sometimes be exploited by cancer cells to escape immune surveillance, leading to resistance to ICIs. Some of these pathways are known to be more commonly mutated in breast cancer, for example, the mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, Wnt/β-catenin pathway and Janus kinase (JAK) and signal transducers and activators of transcription (STAT) pathway. Hence, various combination therapies of ICIs with other therapeutic agents to target each of these specific pathways are gaining traction and have shown promising preliminary activity.
Signalling via the MAPK pathway induces the expression of various proteins such as vascular endothelial growth factor (VEGF) as well as interleukin (IL)-8 that inhibit T cell recruitment and function. Inhibiting the MAPK pathway can also upregulate major histocompatibility complex (MHC)-I, MHC-II, and PD-L1 expression, and enhance infiltration of TILs. Loi et al. had confirmed this observation in an analysis of 111 patients with TNBC who had been treated with neoadjuvant chemotherapy, and demonstrated that alterations in the MAPK signalling pathway can suppress the expression of both MHC-I and MHC-II.
Hence, trials evaluating the combination of mitogen-activated protein kinase kinase (MEK or MAP2K) inhibitors with ICIs are ongoing. The COLET trial was a phase II trial that investigated cobimetinib, a MEK inhibitor, in combination with atezolizumab and taxane chemotherapy in untreated metastatic TNBC. It demonstrated a numerical but nonsignificant increase in ORR of 34.4% and 29% in patients treated with paclitaxel vs. nab-paclitaxel, respectively. Exploratory biomarker analysis suggested that patients with PD-L1-positive disease (defined as IC ≥ 1% by the SP142 IHC assay) had numerically higher ORR compared to those with PD-L1 negative disease (39% vs. 19%), as well as median PFS (7.0 vs. 3.7 months).
Abnormalities in the PI3K/AKT/mTOR pathway are also another well-known mechanism of resistance in breast cancer. The protein phosphatase and tensin homolog (PTEN) tumour suppressor is a negative regulator of PI3K signalling and deletions in PTEN result in the enhancement of PI3K signalling[66,67]. PTEN loss has also been associated with resistance to T cell-mediated immunotherapy by increasing the expression of immunosuppressive cytokines, particularly VEGF. VEGF can contribute further to immunosuppressive TME by recruiting suppressive immune cells such as myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs).
Based on these preclinical findings, AKT inhibitors have been combined with ICIs to overcome this resistance pathway. The phase Ib study evaluating the triplet combination of ipatasertib, atezolizumab, and a taxane as first-line treatment for locally advanced/metastatic TNBC reported a promising ORR of 73% irrespective of their PD-L1 status or PIK3CA/AKT1/PTEN alteration status. The BEGONIA study (NCT03742102) is a phase Ib/II trial evaluating the combination of durvalumab with different novel oncologic therapies designed for immune modulation, with or without paclitaxel as first-line treatment in patients with metastatic TNBC. In arm 2, the addition of capivasertib was studied, yielding an ORR of 53.3%. Importantly, there was a relatively high rate of G3/4 treatment-related adverse events of 73%, although only 6.7% discontinued treatment due to adverse events.
The Wnt/β-catenin pathway is an important oncogenic signalling pathway involved in many essential cellular processes. The activation of Wnt results in the accumulation of the transcriptional co-activator
Interferon γ (IFN-γ) is a cytokine produced by activated T cells and antigen-presenting cells (APCs) that is critical in immune cell activation via the Janus kinase 1 and 2 (JAK1/2) as well as signal transducers and activators of transcription-1 (STAT1) pathway. Any mutation or epigenetic silencing of molecules in this pathway allows tumours to escape its apoptotic or cytostatic effect. A study analysing melanoma patients who were treated with ICI therapy and subsequently developed resistance noted that resistance was associated with defects such as loss-of-function mutations in the JAK1/2 pathway. Another study of 16 melanoma patients observed that those who were non-responders to CTLA-4 inhibition harbor a much higher rate of genomic changes in the IFN-γ pathway genes compared to those who responded.
A crucial feature of adaptive immunity is its ability to recognise antigens that are foreign or not “self”. Cancer cells generally harbour accumulated somatic mutations and genomic instability within DNA coding regions. Antigen peptide sequences that distinguish tumour cells are classified based on their unique cell expression patterns. Tumour-specific antigens (TSA) refer to novel peptide sequences, i.e., neo-antigens, that develop via mutations and are not present in normal healthy cells. Examples of mutations that result in TSAs usually involve oncogenic driver mutations, such as mutations in the BRCA1/2 gene. The presentation of these neoantigens by APCs via MHC-I molecules is critical in priming specific cytotoxic CD8+ T cells, thereby triggering an immune response towards the tumour. Indeed, studies have shown that increasing neoantigen formation helps to improve response to ICIs[81-83].
Similar to the rationale for combining ICIs with chemotherapy which was discussed earlier, antibody-drug conjugates (ADCs) also increase tumour neoantigen formation via immunogenic cell death. An ADC consists of an antigen-specific monoclonal antibody bound to a cytotoxic payload via a molecular linker. The binding of an ADC via its antigen-binding portion induces its internalisation via endocytosis. Once inside the tumour cell, cleavage of its linker through proteolysis results in the release of the cytotoxic payload. This allows for target-dependent activation and selective cytotoxicity. Of note, two ADCs, namely trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, have received FDA approvals for the treatment of specific breast cancer subtypes. T-DXd is approved for unresectable or metastatic HER2-positive breast cancer based on the results of DESTINY-Breast 03, confirming significant PFS benefit (HR 0.28; P < 0.0001), as well as for unresectable or metastatic HER2-low breast cancer based on DESTINY-Breast 04 showing both promising PFS (HR 0.50; P < 0.001) and OS (HR 0.64; P = 0.001) benefit. Sacituzumab govitecan, on the other hand, has been approved both for unresectable or metastatic TNBC as well as hormone-positive, HER2-negative breast cancer based on the ASCENT and TROPiCS-02 trials, respectively, both confirming PFS and OS benefit[88,89].
Preclinical data have suggested that the combination of ADCs with ICIs may improve the efficacy of ICIs via increasing neoantigen formation and presentation, as well as by activating DCs and increasing the expression of PD-L1. There are currently several ongoing trials evaluating the combination of different ADCs with ICIs. In the earlier described BEGONIA study, two ADCs, T-DXd and datopotamab deruxtecan (Dato-DXd), are being studied in arms 6 and 7 of the trial, respectively. Preliminary data for both arms were promising; ORR with the addition of T-DXd was 66.7% and 74% with the addition of Dato-DXd. Other ongoing trials in this space are summarised in Table 2.
Summary of ongoing trials evaluating the addition of ADC to ICI therapy
|Trial name/ID||Phase||Patients enrolled||ICI||ADC||Primary endpoint(s)|
|III||Treatment naïve advanced/metastatic TNBC||Pembrolizumab||Sacituzumab Govitecan||PFS|
|NCT04448886||II||Metastatic HR+/HER2- breast cancer who have progressed on or within 12 months of adjuvant endocrine or ≥ 1 endocrine therapy in the metastatic setting||Pembrolizumab||Sacituzumab Govitecan||PFS|
|NCT03310957||I/II||Advanced/Metastatic TNBC||Pembrolizumab||SGN-LIV1A||ORR, DLT, adverse events|
|Ib/II||Metastatic TNBC||Atezolizumab||Sacituzumab Govitecan or SGN-LIV1A||ORR, adverse events|
|II||Metastatic TNBC||Avelumab||Sacituzumab Govitecan||ORR|
|III||Patients with residual invasive disease in breast/axillary lymph nodes following neoadjuvant chemotherapy||Atezolizumab||Trastuzumab emtansine||Invasive disease-free survival|
|III||Metastatic PD-L1-positive cancer after progression on H +/- P and taxane||Atezolizumab||Trastuzumab emtansine||PFS, OS|
|NCT03032107||I||Metastatic breast cancer on progression on prior H and a taxane||Pembrolizumab||Trastuzumab emtansine||Safety and tolerability|
|NCT04042701||Ib||Metastatic HER2 positive or HER2 low breast cancer||Pembrolizumab||Trastuzumab deruxtecan||DLT and ORR|
|NCT03523572||I||Metastatic breast cancer progressed on ≥ 2 anti-HER2-based regimens||Nivolumab||Trastuzumab deruxtecan||DLT, ORR|
|Ib/II||Metastatic 2nd line and beyond (Part 1) and 1st line (Part 2)||Durvalumab||Trastuzumab deruxtecan||Safety and toxicity|
|I||Advanced or metastatic HER2-low breast cancer||Durvalumab||Trastuzumab deruxtecan||Safety and toxicity|
Poly(ADP-ribose) polymerase inhibitors
Poly(ADP-ribose) polymerase (PARP) inhibitors increase DNA damage, leading to more TSAs and also increased MHC-I expression, thereby causing increased antigen presentation. The increase in DNA damage associated with breast cancer patients who harbour the BRCA1/2 mutation occurs via a process known as synthetic lethality. The use of PARP inhibitors blocks the repair of single-stranded DNA breaks via base excision repair. This allows single-stranded breaks to accumulate, leading to the generation of double-stranded breaks (DSBs). These DSBs can usually be restored by either the high-fidelity homologous repair pathway or the error-prone non-homologous end-joining method. As BRCA1/2 mutant breast cancer patients already have existing defects in homologous repair, they are unable to effectively repair DNA damage, resulting in the generation of TSAs. In addition to increasing antigen presentation, PARP inhibitors have also been shown in preclinical studies to alter the TME by activating intra-tumoural dendritic cells and increasing CD8+ T cell infiltration via the STING (stimulator of interferon genes) pathway. It also enhances the upregulation of PD-L1 expression by reducing the PARylation of STAT3. The latter two mechanisms help to overcome tumour extrinsic mechanisms of resistance to immunotherapy that will be expounded upon later.
Consequently, there have been several studies evaluating the combination of PARPi together with ICIs. The TOPACIO/KEYNOTE-162 trial studied the efficacy of niraparib together with pembrolizumab in 55 patients with metastatic TNBC. In the subgroup of patients with BRCA1/2 mutations, the ORR was 47% and mPFS 8.3 months. In contrast, patients who were non-BRCA1/2 mutants had an ORR of 11% and mPFS of 2.1 months. The MEDIOLA trial studied the combination of olaparib and durvalumab as first or second-line therapy in germline BRCA1/2 mutant metastatic TNBC, noting an ORR of 63%, mPFS of 8.2 months and mOS 21.5 months. Table 3[96-101] summarises some of the available trials evaluating this combination.
Summary of ongoing trials evaluating the addition of PARPi to ICI therapy
|Trial name/ID||Phase||Patients enrolled||ICI||PARPi||Primary endpoint(s)||Results (if any)|
|I/II||Advanced or metastatic TNBC||Pembrolizumab||Niraparib||DLT and ORR||ORR 21%, 47%, 11% (overall, BRCA mutant, BRCA wild-type)|
|NCT04683679||II||Metastatic TNBC or HR+/HER2- breast cancer||Pembrolizumab||Olaparib||ORR|
|NCT03101280||Ib||Previously treated metastatic TNBC with BRCA mutation or BRCA-like molecular signature||Atezolizumab||Rucaparib||Number of dose modifications due to adverse events|
|NCT02849496||II||Advanced or metastatic non-HER2-positive breast cancer with homologous DNA repair deficiency||Atezolizumab||Olaparib||PFS|
|NCT04690855||II||Germline BRCA1/2 negative, PD-L1 positive metastatic TNBC||Atezolizumab||Talazoparib||ORR|
|I/II||Germline BRCA mutated metastatic HER2-negative breast cancer||Durvalumab||Olaparib||DCR, safety, and tolerability||DCR at 12 weeks 80%, 28 weeks 50%
|II||Platinum-treated metastatic TNBC||Durvalumab||Olaparib||PFS||Combination arm: mPFS 6.1 mo, DCR 68.2%|
|II||Advanced ER+, HER2- breast cancer with BRCA mutation, alteration in homologous recombination repair or MSI||Durvalumab||Olaparib||PFS|
|II||Post-neoadjuvant chemotherapy with residual TNBC||Durvalumab||Olaparib||Biomarker study pre-surgery and post-surgery|
|NCT03544125||I||Metastatic TNBC||Durvalumab||Olaparib||Safety and efficacy|
|NCT02484404||I/II||Advanced TNBC||Durvalumab||Olaparib||Dose finding and toxicities|
|JAVELIN PARP Medley
|Ib/II||Advanced/ metastatic TNBC or HR+/HER2- breast cancer||Avelumab||Talazoparib||DLT and ORR||ORR 18.2% and 34.8% (TNBC, HR+/HER2-)|
|II||BRCA or ATM mutant advanced or metastatic solid tumour||Avelumab||Talazoparib||ORR||ORR 26.4% (BRCA) 4.9% (ATM)|
|I/II||Advanced breast cancer||Avelumab||Talazoparib||Safety and toxicities|
|NCT03945604||Ib||Recurrent, metastatic TNBC||Camrelizumab (anti-PD-1)||Fluzoparib||DLT||mPFS 5.2 mo, 12 mo OS 64.2%|
Tumour cells can also evade immune surveillance by altering any step in the antigen presentation pathway, thereby conferring resistance to treatment with ICIs. Several studies involving patients with breast cancer have reported the downregulation of expression of the transporters TAP1, TAP2, and TAPBP, which are necessary for transporting antigens to be loaded onto MHC molecules[102-104]. Other mechanisms that have been observed include loss of heterozygosity and epigenetic suppression of certain MHC-I molecules or alterations in the expression of beta-2-microglobulin (B2M) which is essential for the transport and subsequent expression of MHC-I on the cell surface[105,106]. Luo et al. reported the potential use of DNA methyltransferase inhibitors to overcome resistance to immunotherapy in breast cancer patients.
TUMOUR EXTRINSIC MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY
Alteration of the tumour microenvironment
The TME comprises various components that are constantly evolving, with ongoing crosstalk between tumour and stromal cells, all of which can influence the immune response and drive resistance to ICIs. The presence of TILs in the tumour and its surrounding microenvironment is thought to be a reflection of pre-existing antitumour immunity[49,50], and its presence is thought to be predictive of response to systemic anti-cancer treatment, and a prognostic biomarker. TNBC and HER2-positive breast cancers have a higher number of TILs[51,52]. Other components of the TME include Tregs, MDSCs, tumour-associated macrophages (TAMs), and cytokines.
Tregs suppress effector T cells and APC via secretion of inhibitory cytokines, direct contact, and limiting inflammation. The increased infiltration of Tregs into tumour cells has been observed in several other tumour types[109,110], and murine studies have demonstrated that depleting Tregs from the TME can help to restore antitumour immunity.
The presence of MDSCs in the TME has also been shown to promote angiogenesis, immune evasion, tumour growth and metastasis. A study of patients with melanoma treated with CTLA-4 inhibitors suggested that the increase in MDSCs was associated more often with non-responders. Interestingly, the γ isoform of PI3K has been noted to be highly expressed in MDSC cells in a study of several cancer types, including breast cancer, and selectively inhibiting it can help to re-establish sensitivity to ICIs.
Another important group of cells present in the TME that promote immunosuppression and play a role in resistance to immunotherapy are TAMs, which consist of M1 and M2 macrophages. M1 macrophages are mainly involved in antitumour immunity, while M2 macrophages are pro-tumourigenic. The accumulation of TAMs is regulated by cytokines, such as chemokine ligand 2 (CCL2), which was demonstrated by Qian et al. in their study using breast cancer- bearing murine model, as well as colony-stimulating factor-1 (CSF-1). It was observed to be correlated with increased macrophage infiltration and more frequent metastases in breast cancer patients. Indeed, studies that evaluated CSF-1 receptor inhibition in combination with ICI treatment showed synergy of both agents and promising tumour regression, suggesting that CSF-1 receptor inhibitors can help to overcome tumour resistance to immunotherapy[117,118].
Besides individual populations of cells, the make-up of various cytokines present in the TME is also important in immune cell recruitment, activation, and proliferation by its balance of both stimulatory and suppressive effects. For example, cytokines such as transforming growth factor β (TGF-β) induce immunosuppression by upregulating Tregs and inhibiting cytotoxic T lymphocytes. Tumour cells also express ecto-5’-nucleotidase (CD73), which is an enzyme that dephosphorylates adenosine monophosphate (AMP), forming adenosine. Adenosine is a potent immunosuppressor that binds to A2A receptors found on lymphocytes and suppresses its function. Breast cancer cells have been shown to express CD73, and its expression appears to be regulated by the estrogen receptor (ER), whereby the loss of ER enhances the expression of CD73. A proof of concept study confirmed that anti-CD73 antibody therapy can trigger adaptive antitumour immunity and inhibit metastasis in breast cancer.
Upregulation of other immune checkpoints
Resistance to ICIs can also be achieved via upregulation of other immune checkpoints such as T-cell immunoglobulin, mucin domain-3 protein (TIM-3), LAG-3, V-domain immunoglobulin suppressor of
CONCLUSION: CHALLENGES AND FUTURE DIRECTIONS
Aside from resistance mechanisms to ICIs, there are also many unresolved and unanswered questions that have limited the use of ICIs in breast cancer. These include identifying the best predictive and prognostic biomarkers to guide treatment, evaluating the optimal duration of ICIs in the neoadjuvant/adjuvant setting, and chemotherapy backbone in the metastatic setting, just to name a few. Recent review articles have discussed some of these topics[135,136].
Further advancement in this field needs to be led by sound science with good preclinical evidence from appropriate murine tumour models that can reflect the human immune environment. While this has conventionally largely been restricted due to a limited selection of murine tumour models, novel syngeneic tumour murine models have been better able to mirror the genomic heterogeneity of human cancer, and recapitulate the TME so as to provide accurate results. It is hoped that the use of appropriate novel syngeneic tumour murine models will allow us to further study ICI combinations effectively and accurately.
Lastly, studies looking beyond immunotherapy-based treatments are also being investigated. One such area is the study of the human gut microbiome, a host factor that influences not only the biology of tumour development but also the modulation of its response and resistance to immunotherapy[138-140]. Consequently, there are ongoing studies looking at modifying the gut microbiota in order to increase the efficacy of immunotherapy treatment. These include interventions such as the use of antibiotics, probiotics, faecal microbiota transplantation, and diet and prebiotics.
There is much to be anticipated in this evolving field of immunotherapy in breast cancer. While previously thought to be an immunologically “cold” cancer with limited responses to ICI, this is certainly set to change. The numerous ongoing trials evaluating ICIs in combination with novel therapies to overcome resistance and exploit the immune system, as well as the development of innovative immunomodulatory strategies, will allow us to further harness and expand the role of immunotherapy in breast cancer.
Conceptualization: Wong RSJ, Ong RJM, Lim JSJ
Original draft writing: Wong RSJ, Ong RJM
Manuscript review and editing: Wong RSJ, Lim JSJ
All authors contributed to the article and approved the submitted version.
Availability of data and materials
Financial support and sponsorship
JSJ Lim is supported by the NMRC (NMRC/MOH/00414). All other authors have no funding to declare.
Conflicts of interest
JSJ Lim has received honoraria from Astra Zeneca, Novartis, Roche, DKSH, MSD, Eisai, Pierre Fabre; has advisory activity with Astra Zeneca, Novartis, Roche, DKSH, Pfizer and MSD; received research funding from CTI biopharma, Daiichi Sankyo and Synthon pharmaceuticals; and has received travel grants from Astra Zeneca and MSD.
Ethical approval and consent to participate
Consent for publication
© The Author(s) 2023.
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
2. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022;66:15-23.
3. Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer 2022;3:911-26.
4. Tsai HJ. Clinical cancer chemoprevention: from the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine. Taiwan J Obstet Gynecol 2015;54:112-5.
5. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T 2011;36:197-202.
6. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
7. Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw 2022;22:e2.
8. FDA. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel. [Last accessed on 15 Nov 2023].
9. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma N Engl J Med 2022. pp. 24-34.
10. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387:217-26.
11. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382:810-21.
12. Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol 2018;4:157-8.
13. FDA. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors. [Last accessed on 15 Nov 2023].
14. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460-7.
15. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019;30:397-404.
16. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 2019;30:405-11.
17. Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat 2018;167:671-86.
18. Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019;5:74-82.
19. Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:499-511.
22. Zhang Z, Lu M, Qin Y, et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol 2021;12:672356.
23. Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast cancer immunotherapy: an update. Breast Cancer 2018;12:1178223418774802.
24. Zhao J, Huang J. Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chin Med J 2020;133:853-62.
25. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34.
26. Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol 2020;31:387-94.
27. Zhuang W, Ma J, Chen X, et al. The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel. J Cancer 2018;9:2302-7.
28. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74-88.
29. Garg AD, More S, Rufo N, et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017;6:e1386829.
30. Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol 2019;5:334-42.
31. Tolaney SM, Kalinsky K, Kaklamani VG, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib/II study. Clin Cancer Res 2021;27:3061-8.
32. FDA. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. [Last accessed on 15 Nov 2023].
33. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108-21.
34. Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021;32:994-1004.
35. Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 2021;32:983-93.
36. Weis LN, Tolaney SM, Barrios CH, Barroso-Sousa R. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? NPJ Breast Cancer 2021;7:120.
37. Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. JCO 2021;39:9.
38. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
39. Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020;6:676-84.
40. FDA. Updated time and public participation information: February 9, 2021: meeting of the oncologic drugs advisory committee meeting announcement. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-and-public-participation-information-february-9-2021-meeting-oncologic-drugs-advisory. [Last accessed on 15 Nov 2023].
41. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386:556-67.
42. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020;396:1090-100.
43. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 2022;33:534-43.
44. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019;30:1279-88.
45. Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). JCO 2021;39:506.
46. Conte PF, Dieci MV, Bisagni G, et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial. JCO 2020;38:TPS598.
47. Saji S, Mcarthur HL, Ignatiadis M, et al. ALEXANDRA/IMpassion030: a phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. JCO 2021;39:TPS597.
48. Cortés J, André F, Gonçalves A, et al. IMpassion132 phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol 2019;15:1951-61.
49. de Melo Gagliato D, Buzaid AC, Perez-Garcia J, Cortes J. Immunotherapy in breast cancer: current practice and clinical challenges. BioDrugs 2020;34:611-23.
50. El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group. NPJ Breast Cancer 2021;7:150.
51. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40-50.
52. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-7.
53. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-8.
54. Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol 2019;20:371-82.
55. Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol 2020;21:1283-95.
56. Agostinetto E, Montemurro F, Puglisi F, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers 2022;14:2136.
57. Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol 2023;13:1097983.
58. Goldberg J, Pastorello RG, Vallius T, et al. The immunology of hormone receptor positive breast cancer. Front Immunol 2021;12:674192.
59. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology 2008;22:1233-43.
60. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017;168:707-23.
61. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 2018;173:321-337.e10.
62. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403.
63. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Sci Transl Med 2015;7:279ra41.
64. Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 2016;22:1499-509.
65. Brufsky A, Kim S, Zvirbule Z, et al. Phase II COLET study: atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). JCO 2019;37:1013.
67. Kruger DT, Opdam M, Sanders J, van der Noort V, Boven E, Linn SC. Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. APMIS 2020;128:298-307.
68. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016;6:202-16.
69. Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014;4:70.
70. Schmid P, Loirat D, Savas P, et al. Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res 2019;79:CT049.
71. Schmid P, Nowecki Z, Im SA, et al. Abstract PD10-03: BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). Cancer Res 2022;82:PD10-03.
72. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
73. Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat 2021;190:5-17.
74. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
75. Castagnoli L, Cancila V, Cordoba-Romero SL, et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene 2019;38:4047-60.
76. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
77. Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res 2013;33:162-70.
78. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819-29.
79. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016;167:397-404.e9.
80. Bourré L. Targeting tumor-associated antigens and tumor-specific antigens. Crown Bioscience. Available from: https://blog.crownbio.com/targeting-tumor-associated-antigens-and-tumor-specific-antigens. [Last accessed on 15 Nov 2023].
81. Zou X, Li X, Ke H, et al. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front Immunol 2021;12:689076.
82. Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2022;39:51-60.
84. Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol 2016;102:1-6.
85. Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 2021;23:84.
86. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401:105-17.
87. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9-20.
88. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:1529-41.
89. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402:1423-33.
90. Schmid P, Im SA, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) - Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol 2021;39:1023.
91. Schmid P, Jung KH, Wysocki PJ, et al. 166MO datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study. Ann Oncol 2022;33:S199.
92. Franzese O, Graziani G. Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints. Cancers 2022;14:5633.
93. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers 2020;12:1502.
94. Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019;9:722-37.
95. Ding L, Chen X, Xu X, et al. PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3. Cancer Immunol Res 2019;7:136-49.
96. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019;5:1132-40.
97. Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 2020;21:1155-64.
98. Sammons SL, Tan TJ, Im YH, et al. DORA: a phase II, multicenter, international study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (TNBC). Available from: https://www.tempus.com/wp-content/uploads/2022/12/Sammons_DORA_Poster_SABCS2022-.pdf. [Last accessed on 15 Nov 2023].
99. Yap TA, Bardia A, Dvorkin M, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol 2023;9:40-50.
100. Schram AM, Colombo N, Arrowsmith E, et al. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncol 2023;9:29-39.
101. Zhang Q, Shao B, Tong Z, et al. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med 2022;20:321.
102. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737-42.
103. Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer. PLoS One 2017;12:e0187323.
104. Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology 2017;6:e1305531.
105. Garrido MA, Rodriguez T, Zinchenko S, et al. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics 2018;70:647-59.
106. Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LWK. β2-microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem 2014;14:343-52.
107. Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 2018;9:248.
108. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 2019;39:147-64.
109. Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006;13:1252-8.
110. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
111. Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014;63:247-57.
112. Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 2016;539:437-42.
113. De Henau O, Rausch M, Winkler D, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 2016;539:443-7.
114. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 2014;6:1670-90.
115. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
116. Scholl SM, Pallud C, Beuvon F, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-6.
117. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69.
118. Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014;74:153-61.
119. Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review. J Cell Physiol 2019;234:7983-93.
120. Neel JC, Humbert L, Lebrun JJ. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol 2012;2012:381428.
122. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82.
123. Wang L, Zhou X, Zhou T, et al. Ecto-5’-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008;134:365-72.
124. Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS. Role of estrogen receptor in the regulation of ecto-5’-nucleotidase and adenosine in breast cancer. Clin Cancer Res 2004;10:708-17.
125. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010;107:1547-52.
126. Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016;7:10501.
127. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875-80.
128. Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 2014;26:923-37.
129. Thommen DS, Schreiner J, Müller P, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 2015;3:1344-55.
130. Davar D, Boasberg P, Eroglu Z, et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. In: SITC 2018. p.106-7. Available from: https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/Abstracts/Abstract_Book_Edited_11_20.pdf. [Last accessed on 15 Nov 2023].
131. Ascierto PA, Bono P, Bhatia S, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann Oncol 2017;28:v611-2.
132. Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol 2020;38:9503.
133. Nair VS, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics 2018;10:78.
134. Hong DS, Schoffski P, Calvo A, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. J Clin Oncol 2018;36:3012.
135. Jacobs F, Agostinetto E, Miggiano C, De Sanctis R, Zambelli A, Santoro A. Hope and hype around immunotherapy in triple-negative breast cancer. Cancers 2023;15:2933.
136. Agostinetto E, Losurdo A, Nader-Marta G, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs 2022;31:567-91.
137. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov 2021;11:1368-97.
138. Alpuim Costa D, Nobre JG, Batista MV, et al. Human microbiota and breast cancer - Is there any relevant link? - A literature review and new horizons toward personalised medicine. Front Microbiol 2021;12:584332.
139. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9.
140. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84.
Cite This Article
Wong RSJ, Ong RJM, Lim JSJ. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resist 2023;6:768-87. http://dx.doi.org/10.20517/cdr.2023.58
Wong RSJ, Ong RJM, Lim JSJ. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resistance. 2023; 6(4): 768-87. http://dx.doi.org/10.20517/cdr.2023.58
Wong, Rachel SJ, Rebecca JM Ong, Joline SJ Lim. 2023. "Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies" Cancer Drug Resistance. 6, no.4: 768-87. http://dx.doi.org/10.20517/cdr.2023.58
Wong, RSJ.; Ong RJM.; Lim JSJ. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resist. 2023, 6, 768-87. http://dx.doi.org/10.20517/cdr.2023.58
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at firstname.lastname@example.org.